摘要
乳腺癌是全球范围内女性最常见的癌症,其主要的治疗手段为外科手术,辅以化疗与放疗。随着靶向治疗与抗肿瘤方法的研究不断深入,抗体药物已经受到业界的广泛关注。单克隆抗体(以下简称单抗)药物治疗作用强、不良反应少、患者耐受性高,临床已经将某些单抗药物用于乳腺癌的治疗。目前,FDA已经批准了曲妥珠单抗、帕妥珠单抗、T-DM1以及atezolizumab用于乳腺癌的治疗,多项临床及循证研究显示了上述药物的临床优势。以VEGF和EGFR等为靶点的单抗药物虽获得上市批准,但适应证不包括乳腺癌,近期的研究显示出以此为靶点的单抗药物在乳腺癌患者中的疗效与优势。此外,本文还对目前未上市的在研抗体药物靶点TRAIL/DR5,4-1BB,CD73,ErbB3,TGF-β,IGF-1R与IGF-1/2的机制与研究进展进行介绍,为单抗药物的研究与临床使用提供指导与依据。
Breast cancer is the most common one among women worldwide.The principal treatment for breast cancer is surgery,as well as some well established adjuvant therapies,such as chemotherapy and radiation.With the development of targeted therapy and anti-cancer therapies,the antibody-based therapeutics have been paid extensive attention.Monoclonal antibodies have valid therapeutic effects,limited adverse reactions and are well tolerated.Some monoclonal antibodies have been employed for the treatment of breast cancer.So far,FDA has approved trastuzumab,pertuzumab,ado-trastuzumab emtansine and atezolizumab for breast cancer treatment.Many clinical and evidence-based studies have validated the clinical advantages of these drugs.Although some monoclonal antibodies targeting VEGF,EGFR and so on have been approved by FDA,the indications of which have not included breast cancer.Recent studies present the efficacy and advantages of these monoclonal antibodies in patients with breast cancer.In addition,in order to provide guidance and evidence for the research and clinical use of antibodybased therapeutics,this review also introduces the mechanisms,as well as the progress of research and development,of antibody-based therapeutics targeting TRAIL/DR5,4-1BB,CD73,ErbB3,TGF-β,IGF-1R and IGF-1/2 which have not been approved by FDA.
作者
吴松涛
周双
解染
罗道皇
赵侠
周颖
崔一民
WU Song-tao;ZHOU Shuang;XIE Ran;LUO Dao-huang;ZHAO Xia;ZHOU Ying;CUI Yi-min(Department of Pharmacy,Peking University First Hospital,Beijing 100034,China;Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical Science,Peking University,Beijing 100191,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2019年第24期2954-2959,共6页
Chinese Journal of New Drugs
基金
国家“重大新药创制”科技重大专项资助项目(2017ZX09304028)
关键词
乳腺癌
单抗药物
靶点
研究进展
breast cancer
monoclonal antibody
target
progress of research and development
